Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study

NCT07264010 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

87

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukaemia (AML)
Measurable Residual Disease (MRD)

Interventions

DRUG: Sorafenib (SORA)
DRUG: Venetoclax (VEN)

Sponsor

Nanfang Hospital, Southern Medical University